Stock Comparison

ALNY vs ARWR

Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals Inc

The Verdict

ARWR takes this one.

ALNY

Alnylam Pharmaceuticals, Inc.

8.1

out of 10

Hidden Gem

Winner

ARWR

Arrowhead Pharmaceuticals Inc

8.4

out of 10

Hidden Gem

Head-to-Head

N/A

Market Cap

$9.7B

N/A

P/E Ratio

47.9

N/A

Profit Margin

18.5%

N/A

Return on Equity

36.1%

N/A

Debt-to-Equity

1.3

N/A

Overall Risk

Aggressive

8.1

DVR Score

8.4

The Deep Dive

ALNY8.1/10

Alnylam exhibits a strong, validated RNAi platform with a significant IP moat, multiple approved products, and a clear path to profitability. Positive Phase 3 data for Zilebesiran in hypertension presents a massive TAM expansion catalyst, driving potential for multi-bagger returns. Excellent leadership, strong financials, and robust institutional backing underpin this. However, achieving 10x from ...

Full ALNY Analysis

ARWR8.4/10

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride ...

Full ARWR Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.